Alymsys Q Code: Q5126

Drug & Product Overview

HCPCS Descriptor Injection, bevacizumab-maly, biosimilar, (alymsys), 10 mg

HCPCS Added Date January 1, 2023

Manufacturer Amneal Biosciences

Route of Administration Intravenous

Generic Status Single-Source; Branded

Dosage Type Single-Dose

Dosage Form Injection, Solution

About Alymsys

Alymsys is a medication aligned to the HCPCS Q Code: Q5126 for billing, pricing, and reimbursement purposes in the United States. This Oncology medication is administered via the intravenous route and manufactured by Amneal Biosciences.

According to CMS Drug Use Information: This medication is a man-made antibody (IgG1) used to treat various types of cancer. This drug works by blocking a certain protein (vascular endothelial growth factor-VEGF) thereby decreasing the blood supply to the tumor and slowing tumor growth. This monograph is about the following bevacizumab products: bevacizumab, bevacizumab-adcd, bevacizumab-awwb, bevacizumab-bvzr, bevacizumab-maly, and bevacizumab-nwgd.

Disclaimer: This is a summary and does not contain all possible information about this product. For complete information about this product or your specific health needs, ask your healthcare professional.

NDC Code Information

Based on publicly available CMS files. The list of NDCs below is not exhaustive.

NDC Code	Package	Manufacturer	HCPCS Units	WAC	AWP
85006-1754-01	100 MG / 4 ML Alymsys Intravenous Injection 100 MG/4ML - 1 VIAL in 1 CARTON (85006-1754-1) / 4 mL in 1 VIAL	Valorum Biologics, Llc	10	$757.09 $75.709 / unit	$908.51 $90.851 / unit
85006-1755-01	400 MG / 16 ML Alymsys Intravenous Injection 400 MG/16ML - 1 VIAL in 1 CARTON (85006-1755-1) / 16 mL in 1 VIAL	Valorum Biologics, Llc	40	$3,028.36 $75.709 / unit	$3,634.03 $90.851 / unit

Effective 4/1/26 (WAC & AWP)

Login for the full NDC crosswalk View pricing, complete NDC-to-HCPCS alignments, and package details.

Login →

Alymsys Pricing & Reimbursement

Q5126 Private Payer Reimbursement

$35.87 / HCPCS unit as of Jan 2026

National median reimbursement across major commercial payers.

Create an account on PayerPrice for more information →

Historical Graphing and Billing Calculator

NDC Package

HCPCS Units

Markup / Markdown

%

Common:

Estimates only. Payer reimbursement varies by contract, site of care, and sequestration.

Estimated Reimbursement

Bevacizumab Biosimilar Information:

Alymsys Approval Date: April 13, 2022

Product Name	HCPCS Code	Active Ingredient	BLA Type
Avastin	J9035	Bevacizumab	351(a) Originator Product
Mvasi	Q5107	Bevacizumab	351(k) Biosimilar
Zirabev	Q5118	Bevacizumab	351(k) Biosimilar
Alymsys	Q5126	Bevacizumab	351(k) Biosimilar
Vegzelma	Q5129	Bevacizumab	351(k) Biosimilar
Avzivi	N/A	Bevacizumab	351(k) Biosimilar
Jobevne	Q5160	Bevacizumab	351(k) Biosimilar

Alymsys Claims Performance

Claims from Jan 2026 – Aug 2026

Claim Denial Rate 10.35%

Avg. Days to File 7.4days

Avg. Days to Pay 25.8days

Real-world claims performance from FocalPoint, OnPoint Oncology's reimbursement analytics platform, with claims data accrued at the clearing house level.

Explore Q5126 claims analytics on FocalPoint →

Alymsys CPT Administration Codes

CPT Code	Description
96413	Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug
96415	Chemotherapy administration, intravenous infusion technique; each additional hour (List separately in addition to code for primary procedure)

JW / JZ modifiers apply

CMS has identified Alymsys (Q5126) as a HCPCS code with single-dose containers. Therefore, the JW/JZ wastage modifiers could be required for billing purposes. Wastage billing guide →

Alymsys Medically Unlikely Edits (MUE)

The most billing units of Q5126 Medicare will pay for one patient in one day, as published by CMS. 1 unit = 10 mg.

Practitioner Office & Hospital Outpatient

230 units / day

= 2,300 mg per day

MAI 3 · Date of Service Edit: Clinical. Per-day limit based on clinical expectations; excess units are denied but may be appealed with documentation of medical necessity. See all MUE limits →

Alymsys Clinical Information

Indications and drug classification.

Treated Diseases & Conditions

This list of indications is not exhaustive and may be subject to errors. The information on BuyandBill.com is intended for informational purposes only and should not be used for medical advice.

Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Metastatic Colorectal Cancer Metastatic Renal Cell Carcinoma Non-Squamous Non-Small Cell Lung Cancer Persistent, Recurrent, or Metastatic Cervical Cancer Recurrent Glioblastoma

Drug Class

Vascular Endothelial Growth Factor Inhibitor [EPC]Vascular Endothelial Growth Factor Inhibitors [MoA]Vascular Endothelial Growth Factor-directed Antibody Interactions [MoA]

Frequently Asked Questions

Is there an available Alymsys billing and coding guide?

Our team has not identified a manufacturer-published source of billing and coding information for Alymsys.

Are there any available Alymsys patient assistance programs?

Alymsys patient assistance information can be found through Amneal Biosciences. Visit Here →

Where can I find Alymsys prescribing information?

Alymsys prescribing information can be found at the link below: Visit Here →

Where can I find Alymsys side effect information?

Information regarding Alymsys's side effects can be found at MedlinePlus Visit Here →

Does billing Alymsys require JZ/JW wastage modifiers?

CMS has identified Alymsys(Q5126) as a HCPCS code with single-dose containers. Therefore, the JW/JZ wastage modifiers could be required for billing purposes. See CMS guidelines on use of the JZ and JW wastage modifiers below.

About BuyandBill.com:

The BuyandBill.com team is dedicated to delivering high-quality coding and billing information for office-administered drugs. We continuously research HCPCS-coded medications to expand our resources and ensure data accuracy. Manufacturers: click here to sponsor your medication, and we will ensure the most accurate and detailed information is displayed.